cefotetan disodium - Profile

What are the generic drug sources for cefotetan disodium and what is the scope of patent protection?

Cefotetan disodium is the generic ingredient in four branded drugs marketed by Pai Holdings Pharm, Teligent, Fresenius Kabi Usa, Hikma, West-ward Pharm Corp, and B Braun, and is included in eight NDAs. Additional information is available in the individual branded drug profile pages.

Summary for cefotetan disodium

US Patents:	0
Tradenames:	4
Applicants:	6
NDAs:	8

US Patents and Regulatory Information for cefotetan disodium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pai Holdings Pharm	CEFOTAN	cefotetan disodium	INJECTABLE;INJECTION	050588-001	Dec 27, 1985	AP	RX	Yes	No
Pai Holdings Pharm	CEFOTAN	cefotetan disodium	INJECTABLE;INJECTION	050588-002	Dec 27, 1985	AP	RX	Yes	No
Pai Holdings Pharm	CEFOTAN	cefotetan disodium	INJECTABLE;INJECTION	050588-003	Apr 25, 1988		DISCN	No	No
Teligent	CEFOTAN	cefotetan disodium	INJECTABLE;INJECTION	063293-001	Apr 29, 1993		DISCN	No	No
Teligent	CEFOTAN	cefotetan disodium	INJECTABLE;INJECTION	063293-002	Apr 29, 1993		DISCN	No	No
Pai Holdings Pharm	CEFOTAN IN PLASTIC CONTAINER	cefotetan disodium	INJECTABLE;INJECTION	050694-002	Jul 30, 1993		DISCN	No	No
Pai Holdings Pharm	CEFOTAN IN PLASTIC CONTAINER	cefotetan disodium	INJECTABLE;INJECTION	050694-001	Jul 30, 1993		DISCN	No	No

Cefotetan Disodium: Patent Landscape and Investment Fundamentals

Last updated: February 19, 2026

Cefotetan disodium, a second-generation cephalosporin antibiotic, presents a mixed investment profile driven by established market presence, ongoing patent expiry, and the emergence of antibiotic resistance. While its efficacy against a range of Gram-positive and Gram-negative bacteria underpins current demand, the patent expiration for key formulations necessitates a strategic assessment of market share retention and new development opportunities.

What is the current patent status of cefotetan disodium?

The primary patents covering the synthesis and formulations of cefotetan disodium have largely expired. The original patents for the active pharmaceutical ingredient (API) were filed in the late 1970s and early 1980s. For example, U.S. Patent 4,151,275, related to cephamycin derivatives including cefotetan, was granted in 1979 and expired decades ago. Subsequent patents have focused on specific salt forms, improved delivery methods, or combination therapies.

The expiration of these foundational patents has opened the market to generic manufacturers, leading to increased price competition. For instance, the U.S. Food and Drug Administration (FDA) has approved numerous Abbreviated New Drug Applications (ANDAs) for generic cefotetan disodium. The patent expiry dates for specific formulations and manufacturing processes vary by jurisdiction, but the core intellectual property protection for the molecule itself is no longer in effect in major markets like the United States and the European Union.

Key patent expiration timelines:

• Core API Patents: Expired by the mid-to-late 1990s.
• Specific Salt/Polymorph Patents: Some minor patents may have existed for particular crystalline forms or salt compositions, but these are generally expired or approaching expiration.
• Formulation Patents: Patents related to specific injectable formulations (e.g., lyophilized powder for reconstitution) have also largely expired.

The lack of robust, remaining patent protection for the originator compound means that market exclusivity is primarily driven by regulatory approval, brand recognition, and established supply chains, rather than through a strong, defensible intellectual property moat.

What are the key therapeutic areas and clinical applications for cefotetan disodium?

Cefotetan disodium is primarily utilized as an injectable antibiotic. Its spectrum of activity makes it effective against a variety of bacterial infections.

Primary therapeutic areas include:

• Intra-abdominal Infections: Often used in combination with other agents for the treatment of peritonitis and other intra-abdominal infections caused by susceptible organisms.
• Gynecological Infections: A significant application is in the treatment of pelvic inflammatory disease (PID), endometritis, and other gynecological infections, particularly those involving anaerobic bacteria.
• Lower Respiratory Tract Infections: Can be used for certain types of pneumonia and bronchitis when susceptible bacteria are identified.
• Urinary Tract Infections (UTIs): Effective against some Gram-negative bacteria commonly causing UTIs.
• Skin and Skin Structure Infections: Used for certain types of soft tissue infections.
• Surgical Prophylaxis: Administered preoperatively to reduce the risk of infection following certain surgical procedures, especially in abdominal and gynecological surgery.

The drug's efficacy against certain anaerobic bacteria, such as Bacteroides fragilis, is a key differentiator and contributes to its continued use in specific indications like PID and intra-abdominal infections.

What is the current market size and projected growth for cefotetan disodium?

The global market for cefotetan disodium is mature and characterized by significant generic competition. Precise market size figures are difficult to isolate as many market reports group it within broader cephalosporin or anti-infective categories. However, industry analysis indicates a stable but not rapidly growing market.

Estimated Market Dynamics:

• Market Size: While exact figures vary, the global market for cefotetan disodium is estimated to be in the hundreds of millions of U.S. dollars annually.
• Growth Rate: Projected growth is low, likely in the low single digits (1-3% CAGR) globally. This growth is primarily driven by demand in emerging markets and continued utilization in established markets for specific indications where it remains a cost-effective option.
• Drivers:
  • Continued use in established indications (PID, intra-abdominal infections).
  • Cost-effectiveness compared to newer, patented antibiotics.
  • Demand in hospital settings for parenteral administration.
  • Need for broad-spectrum coverage including anaerobes.
• Restraints:
  • Increasing prevalence of antibiotic resistance.
  • Availability of newer, broader-spectrum, or more convenient antibiotics (e.g., oral formulations, novel classes).
  • Generic price erosion.
  • Regulatory scrutiny and concerns over hospital-acquired infections.

The market is heavily influenced by pricing dynamics due to the large number of generic suppliers. Manufacturers that can achieve cost efficiencies in production and maintain strong distribution relationships in hospital systems are best positioned.

Who are the major manufacturers and suppliers of cefotetan disodium?

The market for cefotetan disodium is populated by both originator companies with legacy products and a significant number of generic manufacturers. The competitive landscape is fragmented.

Key players and their roles:

• Originator/Branded Products:
  • Astellas Pharma: Historically, Astellas (and its predecessor Yamanouchi) was a key developer and marketer of cefotetan disodium under brand names such as Cefotan. While Astellas may still hold some legacy market share or offer branded versions, the primary market driver is now generics.
• Generic Manufacturers (Global):
  • Hikma Pharmaceuticals: A significant player in the generic injectable market, often supplying cefotetan disodium.
  • Fresenius Kabi: A major global supplier of generic IV drugs, including antibiotics.
  • Sandoz (Novartis): A leading global generic pharmaceutical company.
  • Teva Pharmaceutical Industries: Another prominent generic drug manufacturer with a broad portfolio.
  • Mylan (now Viatris): A substantial generic and specialty pharmaceutical company.
  • Indian Manufacturers: Companies like Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, and Lupin are active in API and finished dosage form production for global markets.
  • Chinese Manufacturers: Numerous Chinese API manufacturers are key suppliers to the global generics market.

The supply chain involves API manufacturers, finished dosage form manufacturers, and distributors. Competition is primarily focused on cost, quality, and supply reliability.

What are the competitive advantages and disadvantages for companies involved with cefotetan disodium?

Companies involved with cefotetan disodium face distinct advantages and disadvantages stemming from its market position and patent status.

Competitive Advantages:

• Established Efficacy and Safety Profile: Decades of clinical use provide a well-understood efficacy and safety profile, reducing perceived risk for clinicians and payers.
• Cost-Effectiveness: As a generic drug, it is generally more affordable than newer, patented antibiotics, making it attractive in cost-sensitive healthcare systems and for specific indications.
• Broad-Spectrum Activity (including anaerobes): Its activity against anaerobic bacteria remains a key advantage for specific infection types like PID and intra-abdominal infections.
• Established Hospital Formulary Presence: Existing inclusion in hospital formularies can create inertia and continued demand.
• Mature Manufacturing Processes: Production processes are well-established, allowing for high-volume, efficient manufacturing by experienced players.

Competitive Disadvantages:

• Lack of Patent Protection: No significant remaining patent exclusivity means intense price competition from multiple generic suppliers.
• Antibiotic Resistance: Growing resistance to cephalosporins, including cefotetan, can limit its utility and lead to treatment failures, driving a shift to newer agents.
• Limited Innovation Potential: The molecule is old, offering minimal scope for novel drug delivery systems or new therapeutic indications that could justify significant R&D investment or command premium pricing.
• Competition from Newer Antibiotics: Development of newer antibiotic classes with broader spectra, improved resistance profiles, or better pharmacokinetic properties (e.g., oral bioavailability) directly challenges cefotetan's market share.
• Injectable-Only Formulation: The requirement for intravenous administration limits its convenience compared to oral antibiotics.
• Regulatory Hurdles for New Applications: Developing and obtaining approval for new indications or formulations would require substantial investment with uncertain returns given the generic status of the core molecule.

What is the outlook for cefotetan disodium in the context of antibiotic resistance and pipeline developments?

The outlook for cefotetan disodium is largely tied to the global challenge of antibiotic resistance and the development of next-generation antimicrobials.

Antibiotic Resistance Impact:

• Decreasing Efficacy: Increased resistance rates among common pathogens, including Gram-negative bacteria, can reduce the overall effectiveness of cefotetan disodium, potentially leading to treatment failures and increased mortality. This necessitates careful susceptibility testing before use.
• Shift to Newer Agents: As resistance grows, clinicians are increasingly inclined to use newer antibiotics with improved resistance profiles or broader coverage, especially for severe infections.

Pipeline Developments:

• New Antibiotic Classes: The pharmaceutical pipeline is actively developing novel antibiotics targeting resistant pathogens. These include beta-lactamase inhibitors combined with existing classes, novel beta-lactam structures, and entirely new mechanisms of action. These are likely to displace older agents like cefotetan in many scenarios.
• Combination Therapies: While cefotetan is sometimes used in combination, new fixed-dose combinations of antibiotics are being developed that may offer synergistic activity and broader coverage, potentially reducing reliance on single-agent, older drugs.
• Stewardship Programs: Increased emphasis on antibiotic stewardship programs in healthcare settings aims to optimize antibiotic use, reserving older, broad-spectrum agents for specific, appropriate indications and discouraging their empirical use where newer options are more suitable.

Despite these challenges, cefotetan disodium is likely to retain a niche in specific indications where it remains effective, cost-effective, and where anaerobic coverage is critical, particularly in resource-limited settings or for hospital-acquired infections where empiric therapy options are constrained. However, its growth potential is severely limited, and market share will likely face gradual erosion.

What are the regulatory considerations and compliance requirements?

Manufacturers and marketers of cefotetan disodium must adhere to stringent regulatory standards governing pharmaceutical products, particularly injectables.

Key regulatory aspects include:

• Good Manufacturing Practices (GMP): All manufacturing facilities must comply with GMP regulations (e.g., FDA's 21 CFR Part 210/211, EMA's EudraLex Volume 4) to ensure product quality, purity, and consistency. This includes stringent controls over raw materials, manufacturing processes, and finished product testing.
• Drug Master Files (DMFs): API manufacturers typically maintain DMFs with regulatory agencies (e.g., FDA, EDQM) to provide detailed information on their manufacturing process, quality control, and facility. Finished dosage form manufacturers reference these DMFs in their product applications.
• ANDA Filings (USA): For generic versions in the U.S., companies must file an Abbreviated New Drug Application (ANDA) demonstrating bioequivalence to the reference listed drug (RLD).
• Marketing Authorisation Applications (EU): In Europe, companies seeking to market generic cefotetan disodium must obtain a Marketing Authorisation (MA) through national procedures, mutual recognition, or centralized procedures.
• Pharmacovigilance: Post-market surveillance and reporting of adverse drug events are mandatory. Companies must have robust systems in place to monitor and report any safety signals associated with the product.
• Labeling and Prescribing Information: Product labeling must comply with regulatory requirements, accurately reflecting indications, contraindications, warnings, precautions, and adverse reactions.
• Quality Control and Testing: Rigorous batch testing for identity, strength, quality, and purity is essential. This includes testing for impurities and degradation products.
• Supply Chain Integrity: Ensuring the integrity of the supply chain, from API sourcing to finished product distribution, is crucial to prevent counterfeiting and maintain product quality. This includes requirements for serialization and track-and-trace where mandated.

Compliance with these regulations is non-negotiable for market access and continued sales. Any lapse can lead to product recalls, warning letters, or suspension of manufacturing operations.

What are the potential investment risks and opportunities?

Investing in cefotetan disodium requires a nuanced understanding of its mature market dynamics, competitive pressures, and the broader antibiotic landscape.

Investment Risks:

• Intense Generic Competition: The absence of patent protection leads to significant price erosion and low profit margins for all market participants.
• Antibiotic Resistance: The increasing prevalence of resistance can diminish the drug's efficacy and market relevance, potentially leading to obsolescence for certain indications.
• Limited Growth Prospects: The mature nature of the market and lack of innovation potential mean very low growth prospects, making it a difficult investment for high-growth funds.
• Regulatory Changes: Evolving regulatory requirements for antibiotics, including stricter quality controls or post-market surveillance, can increase compliance costs.
• Competition from Novel Agents: The ongoing development of new antibiotic classes poses a continuous threat of market displacement.
• Commoditization: The product is largely commoditized, with success often hinging on manufacturing cost efficiency and supply chain management rather than innovation or market differentiation.

Investment Opportunities:

• Cost-Efficient Manufacturing: Companies with highly optimized, low-cost manufacturing processes for both API and finished dosage forms can achieve sustainable profitability in this competitive environment.
• Emerging Markets: Continued demand in emerging markets, where cost is a primary driver and newer antibiotics may be less accessible, can offer stable revenue streams.
• Supply Chain Reliability: Companies that can guarantee consistent, high-quality supply to hospitals and large healthcare systems can secure market share and build loyalty.
• Niche Market Focus: Specializing in specific indications where cefotetan disodium remains a preferred choice (e.g., anaerobic infections in specific surgical prophylaxis protocols) can provide a defensible market segment.
• Acquisition of Generic Assets: For well-capitalized entities, acquiring established generic cefotetan disodium portfolios from companies looking to divest could offer a stable cash flow, assuming operational efficiencies can be maintained or improved.
• API Supply to Generics: API manufacturers with superior production economics and quality control can serve the broad global generic market.

Investment in cefotetan disodium is best suited for entities focused on operational efficiency, cost leadership, and stable, albeit low-growth, cash flow generation within the generics sector. It is not typically an investment for companies seeking rapid growth or high-margin innovation in the pharmaceutical space.

Key Takeaways

Cefotetan disodium is a mature antibiotic facing significant headwinds from patent expiration, generic competition, and antibiotic resistance. Its established efficacy and cost-effectiveness secure its place in specific therapeutic niches, particularly for anaerobic infections, but limit its growth potential. Investment opportunities lie in operational efficiency, cost leadership in manufacturing, and stable demand in emerging markets or specific hospital segments.

Frequently Asked Questions

1. Is cefotetan disodium still considered a first-line treatment for any infections? Cefotetan disodium is generally not considered a first-line treatment for most common infections due to evolving resistance patterns and the availability of newer agents. It retains utility as a preferred option for specific indications like pelvic inflammatory disease and certain intra-abdominal infections where its anaerobic coverage is crucial and cost-effectiveness is paramount.

2. What are the main risks associated with generic competition for cefotetan disodium? The primary risk is severe price erosion, leading to significantly reduced profit margins for all manufacturers. This intensifies competition and necessitates extreme cost efficiency in production and supply chain management.

3. How does antibiotic resistance impact the future demand for cefotetan disodium? Increasing resistance to cephalosporins can lead to treatment failures and reduce the drug's overall efficacy, prompting a shift towards newer, more potent antibiotics, thereby diminishing demand for cefotetan disodium over time.

4. Are there any significant remaining patents that could create exclusivity for cefotetan disodium? The foundational patents for cefotetan disodium's synthesis and core formulations have long expired. Any remaining patents are likely to be narrow, covering minor aspects like specific polymorphic forms or manufacturing improvements, and are unlikely to provide substantial market exclusivity.

5. What is the strategic implication of investing in a commoditized antibiotic like cefotetan disodium? Investing in a commoditized antibiotic like cefotetan disodium implies a strategy focused on operational excellence, cost optimization, secure supply chains, and market share defense through competitive pricing, rather than on product innovation or revenue growth from new market segments.

Citations

[1] U.S. Patent 4,151,275. (1979). Cephamycin derivatives. Retrieved from USPTO Patent Database. [2] Food and Drug Administration. (n.d.). Abbreviated New Drug Applications (ANDAs). Retrieved from FDA website. [3] European Medicines Agency. (n.d.). EudraLex - The Rules Governing Medicinal Products in the European Union. Retrieved from EMA website. [4] Astellas Pharma Inc. (n.d.). Product Information: Cefotan (Prescribing Information). (Note: Specific historical product information may be archived or require database access). [5] Industry Market Research Reports (various, anonymized for general market size and growth estimates). [6] Pharmaceutical Regulatory Guidelines (e.g., FDA's 21 CFR Part 210/211, EMA's EudraLex Volume 4 for GMP).